Thyrotoxicosis is less common (1–6.5% of patients), with differences according to drug class having low frequencies with ipilimumab (0.2–1.7%), higher frequency with anti-PD-1/anti-PD-L1 (0.6–3.7%), and the highest frequencies during combination therapy (8.0–11.1%) [10,50]. The gene discussed is CD274; the disease is thyrotoxicosis.